Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

The days are getting shorter as we "fall back” into standard time and it may be affecting your mood. While we settle into our ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive ...